BRKR Shares Climb After Securing New Orders for Its NMR Systems

Bruker Corporation BRKR recently received new orders for advanced Nuclear Magnetic Resonance (“NMR”) instrumentation from the New York Structural Biology Center (“NYSBC”), the University of Delaware and Northwestern University. The NMR systems are supported by the National Institutes of Health (“NIH”) and the National Science Foundation (“NSF”). 

The aggregate value of these three federally funded NMR orders is approximately $10 million, and they are expected to be delivered and installed next year. The latest development is expected to bolster the company’s BioSpin segment. 

BRKR Stock’s Likely Trend Following the News

Since the announcement, shares of Bruker have risen 6.2%, finishing last Friday’s session at $36.98.

Bruker is strategically progressing with its BioSpin’s products that have specific applications in structural proteomics, drug discovery, research, and food and materials science fields, providing customers with the ability to ascertain the structure, dynamics, and function of specific molecules, such as proteins, as well as characterize and determine the composition of mixtures. Accordingly, the latest orders for its NMR systems should continue to boost the market sentiment surrounding BRKR stock.

Bruker has a market capitalization of $5.28 billion. Going by the Zacks Consensus Estimate, the company’s 2025 earnings are expected to increase 2.7%. 

More on Bruker’s NMR Order From NYSBC

NYSBC ordered an NIH-funded Multifield NMR Relaxometry System. This advanced relaxometry system will be the first of its kind in North America, serving a consortium of nine research institutions in New York State as well as the broader national community through the NIH-funded Center on Macromolecular Dynamics by NMR spectroscopy. The system consists of a fast NMR sample shuttle system, a magnetic tunnel, and an electromagnetic field cycling coil (FCC), all mounted on a 700 MHz superconducting NMR magnet.

More on BRKR’s NMR Order From the University of Delaware

At the University of Delaware, the Department of Chemistry and Biochemistry has ordered a 600 MHz Dynamic Nuclear Polarization (DNP) NMR spectrometer, funded by the NSF Major Research Instrumentation program. This instrument will serve over 25 research groups at the University of Delaware and 12 collaborating institutions, supporting projects that range from understanding the molecular basis of disease to developing new materials and sustainable technologies. The new spectrometer’s enhanced sensitivity will enable investigations of complex biological and engineered systems, including intact cells, protein assemblies, polymers, pharmaceutical formulations, and catalysts.

Image Source: Zacks Investment Research

More on Bruker’s NMR Order From Northwestern University

At Northwestern University, the Integrated Molecular Structure Education and Research Center (“IMSERC”) recently ordered an 800 MHz NMR spectrometer. The instrument will benefit over 15 NIH-funded research groups and the broader Chicago research community, including the Chicago Biomedical Consortium. Key research applications include high-resolution biomolecular NMR for drug discovery, protein-ligand interactions, neurodegenerative disease research, regenerative medicine, and advanced materials development.

Industry Prospects Favor BRKR

Per a report by Verified Market Reports, the NMR systems market revenues totaled $2.50 billion in 2024 and are estimated to reach $4.00 billion by 2033, at a CAGR of 5.5% from 2026 to 2033. The primary drivers of the NMR Systems market include the rising demand for advanced analytical solutions across various industries. 

The pharmaceutical sector, in particular, is witnessing an upsurge in the use of NMR for drug discovery and development, necessitating high-precision instruments. Furthermore, growing research activities in academic institutions and laboratories are propelling the demand for NMR systems. 

Another Development by BRKR

Bruker recently signed multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year to date, supporting customers in the aviation security and defense industry to enhance threat detection capabilities.

BRKR Stock Price Performance

Over the past three months, Bruker’s shares have lost 10.4% compared with the industry’s 10.9% decline.

BRKR’s Zacks Rank & Key Picks

Bruker currently has a Zacks Rank #5 (Strong Sell).

Some better-ranked stocks in the broader medical space are Masimo MASI, Phibro Animal Health PAHC and Boston Scientific BSX. While Masimo and Phibro sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Masimo’s shares have jumped 18.9% in the past year. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 13.8%. 

Shares of Phibro have surged 76.5% in the past year compared with the industry’s 3.4% growth. PAHC’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 27.9%.

Shares of Boston Scientific have rallied 16.7% in the past year compared with the industry’s 5.2% growth. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research